Skip to main content
Pfizer COVID-19 vaccine appointments are available to our patients.
Sign up for Connect today
to schedule your vaccination.
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Joint Clinical Trials Office
Explore this Website
Home
About
Toggle About menu options
News
JCTO Contacts
Careers
Our Clinical Trial Locations
Partner with the JCTO
Toggle Partner with the JCTO menu options
JCTO Fees
Open Clinical Trials
Investigators
Patients
Toggle Patients menu options
What is a Clinical Trial?
Frequently Asked Questions
Clinical Trial Questions to Ask Your Healthcare Team
Clinical Trials: Common Terms to Know
Understanding Clinical Trials and How They Work
Understanding Clinical Trials - In Spanish | En Español
Weill Cornell Medicine
Care
Discover
Teach
Home
About
Open Clinical Trials
Investigators
Patients
Home
Clinical Trials
Ongoing Chronic Hepatitis (HCV) Test and Treat Utilizing Simplified HCV Patient Education
Study Status:
Open to Enrollment
Primary Investigator:
Date:
December 30, 2022
A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 2/3 Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients with Symptomatic Polycystic Liver Disease
Study Status:
Open to Enrollment
Primary Investigator:
Date:
December 30, 2022
A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation
Study Status:
Open to Enrollment
Primary Investigator:
Date:
December 30, 2022
A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Subjects with Compensated Cirrhosis
Study Status:
Open to Enrollment
Primary Investigator:
Date:
December 30, 2022
Efficacy and safety investigation of NNC0194-0499 co-administered with semaglutide in subjects with non-alcoholic steatohepatitis: a dose-ranging placebo-controlled trial
Study Status:
Open to Enrollment
Primary Investigator:
Date:
December 30, 2022
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C)
Study Status:
Open to Enrollment
Primary Investigator:
Date:
February 7, 2023
Phase IA Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich’s Ataxia
Study Status:
Open to Enrollment
Primary Investigator:
Date:
February 13, 2023
A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-Tumor Activity Study of IMM-1-104, A Novel Oral Dual MEK1/2 Inhibitor in Participants with Previously Treated RAS-Mutated Advanced or Metastatic Solid Tumors
Study Status:
Open to Enrollment
Primary Investigator:
Date:
February 16, 2023
A Phase 2A, Randomized, Double-Blind, Placebo-controlled, Clinical Trial Evaluating the Safety and Efficacy of CM-101 in Subjects with Primary Sclerosing Cholangitis - The Spring Study
Study Status:
Open to Enrollment
Primary Investigator:
Date:
March 6, 2023
Whole-Food Plant-Based Diet (WFPBD) to Control Weight and Metabo-Inflammation in Overweight/Obese Men with Prostate Cancer Receiving Androgen Deprivation Therapy (ADT): A Multi-Center Randomized Control Trial
Study Status:
Open to Enrollment
Primary Investigator:
Date:
March 16, 2023
« first
‹ previous
…
8
9
10
11
12
(current)
13
14
15
16
…
next ›
last »